Piperacillin/tazobactam-induced immune-mediated thrombocytopenia in the intensive care unit

Area of Science:

• Critical Care Medicine
• Pharmacology
• Hematology

Background:

• Drug-induced immune-mediated thrombocytopenia is a rare but serious adverse event.
• Diagnosing thrombocytopenia in critically ill patients presents significant challenges.
• Piperacillin/tazobactam has been rarely associated with rapid and profound thrombocytopenia.

Observation:

• A 64-year-old male experienced recurrent isolated thrombocytopenia following piperacillin/tazobactam administration.
• Thrombocytopenia severity correlated with concurrent corticosteroid dosage.
• Extensive workup excluded other causes of thrombocytopenia in this complex patient.

Findings:

• This report describes the first case of piperacillin/tazobactam-induced immune-mediated thrombocytopenia.
• Corticosteroid therapy was effective in mitigating the thrombocytopenia.
• The findings suggest a potential therapeutic role for corticosteroids in this specific drug reaction.

Implications:

• Highlights the critical need to consider drug-induced thrombocytopenia in differential diagnoses.
• Underscores the importance of vigilant monitoring for adverse drug reactions in critical care settings.
• Suggests corticosteroid therapy as a potential management strategy for piperacillin/tazobactam-induced thrombocytopenia.